The chart of Supernus Pharmaceuticals Inc (SUPN) shows a double top with $25.24 target or 3.00% above today’s $24.50 share price. The 7 months chart pattern indicates low risk for the $1.19 billion company. It was reported on Jan, 11 by Finviz.com. If the $25.24 price target is reached, the company will be worth $35.70 million more. Double tops are rare but powerful chart patterns. About 182,282 shares traded hands. Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has risen 33.16% since June 7, 2016 and is uptrending. It has outperformed by 25.74% the S&P500.
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Ratings Coverage
Out of 4 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 2 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 50% are positive. $32 is the highest target while $27 is the lowest. The $29 average target is 18.37% above today’s ($24.5) stock price. Supernus Pharmaceuticals has been the topic of 7 analyst reports since August 26, 2015 according to StockzIntelligence Inc. The rating was initiated by Northland Capital with “Outperform” on Wednesday, October 28. The stock of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has “Market Perform” rating given on Monday, July 18 by Northland Capital. The company was downgraded on Monday, July 18 by Piper Jaffray. The firm has “Outperform” rating by Northland Capital given on Thursday, November 5. The firm earned “Hold” rating on Wednesday, August 26 by Zacks. Jefferies maintained Supernus Pharmaceuticals Inc (NASDAQ:SUPN) rating on Thursday, August 4. Jefferies has “Buy” rating and $28 price target.
According to Zacks Investment Research, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.”
Insitutional Activity: The institutional sentiment decreased to 1.04 in Q3 2016. Its down 0.22, from 1.26 in 2016Q2. The ratio dived, as 15 funds sold all Supernus Pharmaceuticals Inc shares owned while 85 reduced positions. 29 funds bought stakes while 75 increased positions. They now own 45.01 million shares or 1.35% less from 45.62 million shares in 2016Q2.
Eventide Asset Mngmt Lc last reported 0.67% of its portfolio in the stock. Blackrock Advsr Ltd Liability Com has 0% invested in the company for 34,951 shares. Granahan Inv Mngmt Ma reported 807,049 shares or 0.65% of all its holdings. Oxford Asset Mgmt accumulated 0.13% or 129,825 shares. Eam Investors Lc has invested 0.48% of its portfolio in Supernus Pharmaceuticals Inc (NASDAQ:SUPN). Nicholas Invest Prtnrs Limited Partnership has 136,776 shares for 0.22% of their US portfolio. Price T Rowe Assocs Md has 0% invested in the company for 22,685 shares. Finemark National Bank Tru has invested 0% of its portfolio in Supernus Pharmaceuticals Inc (NASDAQ:SUPN). Legal General Group Public Limited Liability accumulated 41,249 shares or 0% of the stock. Castleark Ltd Liability Company last reported 358,376 shares in the company. Mckinley Mngmt Limited Co Delaware holds 315,444 shares or 0.24% of its portfolio. The Minnesota-based White Pine Cap Limited Liability has invested 0.29% in Supernus Pharmaceuticals Inc (NASDAQ:SUPN). Moreover, State Common Retirement Fund has 0.01% invested in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) for 277,850 shares. Moreover, Texas Permanent School Fund has 0.01% invested in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) for 37,715 shares. Osborn Rohs Williams & Donohoe Limited owns 9,000 shares or 0.04% of their US portfolio.
Insider Transactions: Since September 16, 2016, the stock had 0 buys, and 1 insider sale for $50,000 net activity. $50,000 worth of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) was sold by PATRICK GREGORY S.
SUPN Company Profile
Supernus Pharmaceuticals, Inc. (Supernus), incorporated on March 30, 2005, is a pharmaceutical firm focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Firm offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It is also engaged in developing multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD). The Company’s psychiatry product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). It is also developing SPN-810 as a treatment for IA in patients who have ADHD and SPN-812 for the treatment of ADHD. It is also developing SPN-809 (viloxazine hydrochloride) for the treatment of depression. The Firm markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.